US 12,252,518 B2
Methods of treating non-arteritic anterior ischemic optic neuropathy
Michel Wathier, Boston, MA (US); Jennifer Cermak, Boston, MA (US); and Joan Mannick, Boston, MA (US)
Assigned to Life Biosciences, Inc., Boston, MA (US)
Filed by Life Biosciences, Inc., Boston, MA (US)
Filed on May 4, 2023, as Appl. No. 18/312,538.
Claims priority of provisional application 63/499,864, filed on May 3, 2023.
Claims priority of provisional application 63/478,843, filed on Jan. 6, 2023.
Prior Publication US 2024/0228561 A1, Jul. 11, 2024
Int. Cl. A61K 48/00 (2006.01); A61K 31/65 (2006.01); A61P 25/02 (2006.01); C07K 14/47 (2006.01); C12N 15/86 (2006.01); C07H 21/04 (2006.01)
CPC C07K 14/4702 (2013.01) [A61K 31/65 (2013.01); A61P 25/02 (2018.01); C12N 15/86 (2013.01); A61K 48/005 (2013.01); A61K 48/0058 (2013.01); C07H 21/04 (2013.01)] 30 Claims
 
1. A method for treating non-arteritic anterior ischemic optic neuropathy (NAION) in a subject in need thereof,
the method comprising intravitreally administering, to one or both eyes of a subject treated with a tetracycline-class antibiotic before, during and/or after the administering step, pharmaceutically effective amounts of:
a first adeno-associated virus (AAV) expression vector comprising a first polynucleotide encoding octamer-binding transcription factor 4 (OCT4), sex determining region Y box 2 (SOX2), and Kruppel-like factor 4 (KLF4), but not Myc proto-oncogene (c-Myc), operatively linked to a tetracycline response element (TRE) promoter and flanked by inverted terminal repeats (ITRs), and
a second adeno-associated virus (AAV) expression vector comprising a second polynucleotide encoding a reverse tetracycline transactivator, operatively linked to a promoter and flanked by inverted terminal repeats (ITRs) wherein the method increases the number of healthy axons, enhances axon survival compared to vehicle treatment, improves retinal ganglion cell (RGC) function, or a combination thereof.